Ario Pharma Strengthens Scientific Advisory Board with Two Key Appointments
maio 23, 2014
PDF 106,4 KB
DownloadInnovation in respiratory medicine.
Ario Pharma is a clinical-stage company developing a novel therapeutic approach to overactive bladder, an area of significant unmet medical need.
The Company’s development compound, XEN-D0501, targets a well-established, but not yet exploited mechanism for overactive bladder, and is about to start Phase two clinical development.
Industry
Biotech
Status
Realised
Location
UK